Urinary tract infections (UTIs) are common bacterial infections affecting any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Escherichia coli is a predominant causative agent, but other bacteria, viruses, or fungi can also lead to UTIs. Symptoms of UTIs may include frequent and painful urination, a strong urge to urinate, cloudy or foul-smelling urine, and pelvic pain. UTIs are more prevalent in women due to the shorter urethra, making it easier for bacteria to reach the bladder. Factors like sexual activity, urinary tract abnormalities, and a weakened immune system can increase the risk of UTIs. Diagnosis involves urine analysis, and treatment typically includes antibiotics to eliminate the infecting bacteria. Preventive measures include staying hydrated, practicing good hygiene, avoiding irritants like harsh soaps, and emptying the bladder regularly. Ongoing research focuses on understanding bacterial resistance, optimizing treatment regimens, and developing alternative preventive strategies for UTIs.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States